Comparison of B‐type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease

[1]  B. Celli,et al.  Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. , 2006, Respiratory care.

[2]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[3]  F. Rutten,et al.  Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study , 2005, BMJ : British Medical Journal.

[4]  F. Rutten,et al.  Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. , 2005, European heart journal.

[5]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[6]  A. Jaffe,et al.  Quality specifications for B-type natriuretic peptide assays. , 2005, Clinical chemistry.

[7]  R. Rodeheffer.  Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? , 2004, Journal of the American College of Cardiology.

[8]  K. Bailey,et al.  Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study , 2004, Circulation.

[9]  M. Frenneaux,et al.  Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys system. , 2004, Clinical chemistry.

[10]  Diederick E Grobbee,et al.  Test research versus diagnostic research. , 2004, Clinical chemistry.

[11]  James D. Thomas,et al.  Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. , 2004, Journal of the American College of Cardiology.

[12]  N. Klitgaard,et al.  N‐terminal pro‐brain natriuretic peptide for discriminating between cardiac and non‐cardiac dyspnoea , 2004, European journal of heart failure.

[13]  M. Nieminen,et al.  Clinical applications of B-type natriuretic peptide (BNP) testing. , 2003, European heart journal.

[14]  C. Frampton,et al.  Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. , 2003, Journal of the American College of Cardiology.

[15]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[16]  J. Hollander,et al.  Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[17]  David Moher,et al.  The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration , 2003, Annals of Internal Medicine [serial online].

[18]  James B Seward,et al.  Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. , 2002, The American journal of cardiology.

[19]  D. Levy,et al.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.

[20]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[21]  Diederick E Grobbee,et al.  When should we remain blind and when should our eyes remain open in diagnostic studies? , 2002, Journal of clinical epidemiology.

[22]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.

[23]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[24]  M. Landray,et al.  Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study , 2000, BMJ : British Medical Journal.

[25]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[26]  S G Thompson,et al.  Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.

[27]  Mario J. Garcia,et al.  New Doppler echocardiographic applications for the study of diastolic function. , 1998, Journal of the American College of Cardiology.

[28]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[29]  E. Clini,et al.  Echo-Doppler evaluation of left ventricular impairment in chronic cor pulmonale. , 1996, Chest.

[30]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[31]  E. J. Benjamin,et al.  Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. , 1996, Archives of internal medicine.

[32]  A. Richards,et al.  The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. , 1995, Biochemical and biophysical research communications.

[33]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[34]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[35]  B. Lipworth,et al.  Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. , 1992, Clinical science.

[36]  J. Remes,et al.  Validity of clinical diagnosis of heart failure in primary health care. , 1991, European heart journal.

[37]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[38]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[39]  R R Miller,et al.  A New, Simplified and Accurate Method for Determining Ejection Fraction with Two‐dimensional Echocardiography , 1981, Circulation.

[40]  C L Feldman,et al.  Assessment of Left Ventricular Ejection Fraction and Volumes by Real-time, Two-dimensional Echocardiography: A Comparison of Cineangiographic and Radionuclide Techniques , 1979, Circulation.

[41]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.

[42]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[43]  W. Abelmann,et al.  Assessment of Left Ventricular Ejection Fraction and Volumes by Real-time , Two-dimensional Echocardiography A Comparison of Cineangiographic and Radionuclide Techniques , 2022 .